Press release

January 2017

Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

January 9, 2017

– Marketing Authorization Application is expected to be filed in mid-2017 NEWS PROVIDED BY Sorrento Therapeutics, Inc. Jan 09, 2017, 09:00 ET SAN DIEGO, Jan. 9, 2017 /PRNewswire/ — SCILEX Pharmaceuticals Inc. (“SCILEX”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that its pivotal study for its lead investigational product, ZTlido™ (lidocaine patch … Continue reading Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™
X

Share This Page

XS SM MD LG XL